Eli Lilly's Alzheimer's Drug Candidate Slows Progression By 60% In Mildly Impaired Patients
Portfolio Pulse from Vandana Singh
Eli Lilly has presented full results from the Phase 3 TRAILBLAZER-ALZ 2 study showing that its Alzheimer's drug candidate, donanemab, significantly slowed cognitive and functional decline in early symptomatic Alzheimer's patients. The submission to the FDA for traditional approval was completed last quarter, with regulatory action expected by the end of the year.
July 17, 2023 | 6:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's Alzheimer's drug candidate, donanemab, has shown significant efficacy in Phase 3 trials. This could potentially boost the company's stock if the drug receives FDA approval.
The successful trial results of Eli Lilly's Alzheimer's drug candidate, donanemab, could potentially lead to FDA approval. This would likely result in increased revenues for the company, thereby boosting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100